In vitro Effect of Bisphosphonates on Squamous Cell Carcinoma from Tongue Tissue

被引:0
作者
Balean, Octavia Iulia [1 ]
Galuscan, Atena [1 ]
Jumanca, Daniela [1 ]
Farcas, Claudia [2 ]
Coricovac, Dorina [2 ]
Chioran, Doina [3 ]
Lazureanu, Voichita [4 ]
Podariu, Angela Codruta [1 ]
机构
[1] Univ Med & Farm Timisoara, Fac Dent Med, Dept 1, 14A Splaiul Tudor Vladimirescu, Timisoara 300173, Romania
[2] Victor Babes Univ Med & Pharm, Fac Pharm, 2 Eftimie Murgu Sq, Timisoara 300041, Romania
[3] Univ Med & Farm Timisoara, Fac Dent Med, Dept 2, 5 Take Ionescu, Timisoara 300062, Romania
[4] Univ Med & Farm Timisoara, Fac Med, 2 Eftimie Murgu Sq, Timisoara 300041, Romania
来源
REVISTA DE CHIMIE | 2019年 / 70卷 / 02期
关键词
bisphosphonates; tongue squamous cell carcinoma; cell viability; POTENTIAL ANTICANCER PROPERTIES;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The purpose of this in vitro study was to evaluate the efficacy of three different types of bisphosphonates: Actonel (risedronate sodium), Fosamax (alendronic acid) and Ossica (ibandronic acid) on a squamous carcinoma cell line (SCC-4) with tongue tissue origin. The cell viability was assessed after a stimulation period of 24h and the Alamar Blue test was performed. The assessment revealed that the viability of squamous cell carcinoma was slightly reduced after treatment with the smallest concentration of bisphosphonates, with a lowest rate (89%) recorded for Actonel. When a concentration of 2 and 2.5 mu M was used, the cell viability was between 85-89% independently of the type of bisphosphonates used. The higher concentrations of 3 mu M, 4 mu M showed a significant reduction of 72% when using Fosamax, and 68% when using Ossica. We can state that the viability of tongue squamous cell carcinoma cells decreases as the concentration of bisphosphonates used increases.
引用
收藏
页码:663 / 666
页数:4
相关论文
共 11 条
[1]   Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells [J].
Acil, Yahya ;
Arndt, Mia Leena ;
Guelses, Aydin ;
Wieker, Henning ;
Naujokat, Hendrik ;
Ayna, Mustafa ;
Wiltfang, Joerg .
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2018, 46 (04) :538-546
[2]  
Berenson James R, 2011, Curr Opin Support Palliat Care, V5, P233, DOI 10.1097/SPC.0b013e328349dc17
[3]   Anti-Tumour Effects of Bisphosphonates - What have we Learned from In Vivo Models? [J].
Brown, H. K. ;
Holen, I. .
CURRENT CANCER DRUG TARGETS, 2009, 9 (07) :807-823
[4]   Potential Anticancer Properties of Bisphosphonates: Insights From Preclinical Studies [J].
Clezardin, Philippe .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (02) :102-113
[5]   Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class [J].
Clezardin, Philippe .
BONE, 2011, 48 (01) :71-79
[6]   Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature [J].
Gnant, Michael ;
Clezardin, Philippe .
CANCER TREATMENT REVIEWS, 2012, 38 (05) :407-415
[7]   Potential Anticancer Properties of Bisphosphonates [J].
Neville-Webbe, Helen L. ;
Gnant, Michael ;
Coleman, Robert E. .
SEMINARS IN ONCOLOGY, 2010, 37 (03) :S53-S65
[8]   Biochemical and molecular mechanisms of action of bisphosphonates [J].
Rogers, Michael J. ;
Crockett, Julie C. ;
Coxon, Fraser P. ;
Monkkonen, Jukka .
BONE, 2011, 49 (01) :34-41
[9]   Bisphosphonates: The first 40 years [J].
Russell, R. Graham G. .
BONE, 2011, 49 (01) :2-19
[10]   Bisphosphonates in cancer therapy [J].
Stresing, Verena ;
Daubine, Florence ;
Benzaid, Ismahene ;
Moenkkoenen, Hannu ;
Clezardin, Philippe .
CANCER LETTERS, 2007, 257 (01) :16-35